Cubist Systematic Strategies LLC acquired a new position in Myovant Sciences Ltd (NYSE:MYOV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 36,479 shares of the company’s stock, valued at approximately $330,000.
Other hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC bought a new stake in Myovant Sciences in the second quarter worth about $60,000. Northern Trust Corp bought a new stake in Myovant Sciences in the second quarter worth about $105,000. Virtus ETF Advisers LLC bought a new stake in Myovant Sciences in the second quarter worth about $279,000. BlackRock Inc. raised its position in Myovant Sciences by 59.1% in the second quarter. BlackRock Inc. now owns 44,637 shares of the company’s stock worth $404,000 after acquiring an additional 16,580 shares during the period. Finally, Swiss National Bank raised its position in Myovant Sciences by 134.0% in the second quarter. Swiss National Bank now owns 73,000 shares of the company’s stock worth $661,000 after acquiring an additional 41,800 shares during the period. 40.29% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently issued reports on the stock. Svb Leerink assumed coverage on shares of Myovant Sciences in a research report on Monday, August 19th. They issued an “outperform” rating and a $26.00 price target on the stock. Cowen reissued a “buy” rating on shares of Myovant Sciences in a research report on Friday, September 6th. Goldman Sachs Group assumed coverage on shares of Myovant Sciences in a research report on Wednesday, August 28th. They issued a “buy” rating and a $20.00 price target on the stock. Leerink Swann assumed coverage on shares of Myovant Sciences in a research report on Monday, August 19th. They issued an “outperform” rating and a $26.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Myovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $22.18.
Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.06. Equities analysts expect that Myovant Sciences Ltd will post -3.13 EPS for the current year.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
See Also: What is the definition of a trade war?
Want to see what other hedge funds are holding MYOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myovant Sciences Ltd (NYSE:MYOV).
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.